Journal of Biochemistry Advance Access published online on May 28, 2008
Journal of Biochemistry, doi:10.1093/jb/mvn072
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 The Japanese Biochemical Society
ATP-binding on fibroblast growth factor 2 partially overlaps with the heparin binding domain
Institut für Pharmazeutische und Medizinische Chemie, Westfälische Wilhelms-Universität Münster, Hittorfstr. 58-62, 48149 Münster, Germany
*To whom correspondence should be addressed: Prof. Josef Krieglstein, Tel.: 049(0)2518332210; Fax:049(0)2518332211, E-mail: krieglst{at}uni-muenster.de
Received March 13, 2008; Accepted May 20, 2008
| Abstract |
|---|
Summary
Fibroblast growth factor 2 (FGF2), an intensively studied heparin-binding cytokine, is an important modulator of cell growth and differentiation under both physiological and pathophysiological conditions. It has been shown recently that ATP binds to FGF2 and that this binding is crucial for its biological function. In this study we demonstrated that divalent cations were not necessary for binding of ATP to FGF2, but it could be demonstrated that heparin blocked the labeling of FGF2 with ATP indicating an involvement of the heparin binding domain (aa 128-144) in ATP binding. FGF2, bound to Heparin Sepharose, could be eluted with ATP and GTP, but not with cAMP, AMP or ADP. Successive mutation of positively charged amino acid residues located in the heparin binding domain drastically reduced the signal intensity of [
-32P]ATP labeled FGF2 indicating that this domain is not only important for heparin binding to FGF2 but also for ATP binding.
Key Words: ATP, heparin, bFGF, FGF2, heparin-binding domain, complex